Herhangi bir kurum tarafından destek almamıştır.
The novel coronavirus disease 2019 (COVID-19) emerged in China in late December 2019 and quickly spread to many countries around the world. Antiviral drugs are candidate treatments for the treatment of COVID-19. Molnupiravir, the first oral antiviral drug, is a drug with anti-RNA polymerase activity and is currently being used for the treatment of COVID-19 patients. In this review, we aimed to discuss the mechanism of action, safety, efficacy and clinical studies of molnupiravir in the treatment of patients with COVID-19.
| Birincil Dil | İngilizce |
|---|---|
| Konular | Acil Tıp |
| Bölüm | Derleme |
| Yazarlar | |
| Gönderilme Tarihi | 1 Mayıs 2022 |
| Kabul Tarihi | 6 Kasım 2022 |
| Yayımlanma Tarihi | 30 Aralık 2022 |
| Yayımlandığı Sayı | Yıl 2022 Cilt: 4 Sayı: 3 |